Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

How to elevate your communications testing with AI powered insights and analytics

Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

Inizio

- PMLiVE

COVID-19’s consequences

COVID-19 vaccines might rhyme with antibiotics

- PMLiVE

Longitude Prize on Dementia launches innovator hackathons to those aiming for £1m grand prize

The prize will award a total of £4.34m for technology-based tool for people living with dementia

- PMLiVE

Millions invited to take part in UK’s largest health research programme

Eventually up to five million people will have the opportunity to join Our Future Health

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

One to two people per million are diagnosed with paroxysmal nocturnal haemoglobinuria each year

- PMLiVE

Gilead’s latest Biktarvy data offers hope to HIV patients

The data was shared at the 30th International Congress on Drug Therapy in HIV Infection

- PMLiVE

New study links genetic traits of Black Death survivors and autoimmune diseases today

The study involved the extraction and screening of more than 500 ancient DNA samples

Patient Programmes Sponsor

Celebrating award-winning patient-centricity

Every year, Cuttsy+Cuttsy choose to sponsor 'Patient Programmes' at the PM Society Digital awards. Here's why.

Cuttsy + Cuttsy

Digital Content Council: A Customer Story

Real-world methodology & results from hosting an ongoing, nationwide Digital Content Council...

Impetus Digital

- PMLiVE

CAR-T cell therapy in oncology

By Brian Huber and Tamie Joeckel

- PMLiVE

AbbVie to acquire DJS Antibodies in $255m cash deal

The agreement includes DJS-002, an experimental drug for idiopathic pulmonary fibrosis

- PMLiVE

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

Phase 3 trial results demonstrated a 22% reduction in risk of death versus sorafenib

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links